Premium
Clinical characteristics and treatment outcome of children with acute lymphocytic leukemia and down's syndrome. A pediatric oncology group study
Author(s) -
Ragab Abdelsalam H.,
AbdelMageed Aly,
Shuster Jonathan J.,
Frankel Lawrence S.,
Pullen Jeanette,
Van Eys Jan,
Sullivan Margaret P.,
Boyett James,
Borowitz Michael,
Crist William M.
Publication year - 1991
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19910215)67:4<1057::aid-cncr2820670432>3.0.co;2-k
Subject(s) - medicine , hepatosplenomegaly , acute lymphocytic leukemia , immunophenotyping , tumor lysis syndrome , chemotherapy , etoposide , vincristine , univariate analysis , incidence (geometry) , cohort , leukemia , pediatrics , immunology , cyclophosphamide , lymphoblastic leukemia , multivariate analysis , flow cytometry , physics , disease , optics
Of 2947 children with acute lymphocytic leukemia (ALL), treated during three consecutive studies of the Pediatric Oncology Group (1974–1986), 52 (1.8%) had Down's Syndrome (DS). Comparison of clinical and laboratory characteristics showed no significant differences in leukocyte count, racial distribution, sex ratio, platelet count, incidence of mediastinal mass, lymphadenopathy or hepatosplenomegaly, or percentage of blood or bone marrow blasts for children with ALL with or without Down's Syndrome (DS‐ALL or NDS‐ALL, respectively). However, children with DS‐ALL were slightly older at the time of presentation and had higher hemoglobin values. The relative frequency of each major immunophenotype (early pre‐B, pre‐B, T, or B) was also comparable for patients with or without DS. For this report, treatment regimens were categorized as either conventional (no consolidation therapy) or intensive. Cox regression analysis revealed that the presence of DS, a higher leukocyte count, black race, or age older than 10 years was independently associated with a poorer event‐free survival (EFS) for children treated with conventional chemotherapy. However, for the cohort of children who received intensive chemotherapy, DS was no longer an independent risk factor. In fact, event‐free survival (EFS) was markedly improved to a level comparable with that observed in the children diagnosed as having NDS‐ALL. On the other hand, serious toxicity, requiring interruption of treatment, was significantly more frequent in the intensively treated children with DS compared with similarly treated patients with NDS‐ALL, although deaths resulting from toxicity occurred infrequently.